

[REDACTED]

Second Simple Letter Agreement Amending Inter-Institutional Agreement

This Second Simple Letter Agreement (the “**2nd SLA**”) concluded and effective on the date of November 22, 2023, is between The Johns Hopkins University, a Maryland corporation having an address at 3400 N. Charles St., Baltimore, MD 21218 (“**JHU**”) and The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, v.v.i. (Ústav organické chemie a biochemie AV ČR, v.v.i.), having an address at Flemingovo nam. 2, 16610 Prague 6, Czech Republic (“**IOCB**”). JHU and IOCB shall be known as the “**Parties**.”

1. JHU controls, through the inter-institutional agreement with IOCB dated 23 September 2020 (JHU Agreement Number A36614) as first amended via the Simple Letter Agreement dated 10 February 2022 (JHU Agreement Number A40239), and as further amended via the First Amendment dated 23 January 2023 (JHU Agreement Number A41759) (the “**IIA**”), commercial rights in and to certain valuable inventions and technologies jointly owned by JHU and IOCB, and wholly owned by JHU, as specifically outlined in **Exhibit A** to this Agreement.
2. JHU and IOCB have entered into a Non-Disclosure, Evaluation, and Option Agreement with Sun Pharma Advanced Research Company Ltd., an Indian corporation with Registered Office at Plot No. 5&6/1, Savli G.I.D.C. Estate, Savli – Vadodara Highway, Manjusar - 391775, Dist.-Vadodara, Gujarat, India and corporate office at 17/B Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India (“**SPARC**”), dated February 11, 2021 (JHU Agreement Number A38209), as first amended via the First Amendment dated 14 February, 2022 (JHU Agreement Number A40177), and as further amended via the Second Amendment dated 18 July 2022 (JHU Agreement Number A42885) (the “**Option Agreement**”) for the purpose of developing, manufacturing, using and/or distributing products and services in accordance with the Option Agreement.
3. The Parties extended the term of the Option for twelve (12) months and attached the financial terms for the prospective License Agreement to the First Amendment to the Option Agreement (“**1st Amendment**”).

4. [REDACTED]

(i) [REDACTED]

(ii) [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

5. For the purposes of distributing any income under the Option Agreement and the prospective License Agreement (collectively the “**Agreements**”), the Parties hereby agree to allocate equal value to each technology under the Agreements.

6. [REDACTED]

(i) [REDACTED]

(ii) [REDACTED]

7. [REDACTED]

8. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

9. All other terms and conditions of the IIA not herein amended remain binding and in effect.

[REDACTED]

[REDACTED]

IN WITNESS WHEREOF, JHU and IOCB have caused this Agreement to be duly executed as indicated below:

THE JOHNS HOPKINS UNIVERSITY

**INSTITUTE OF ORGANIC CHEMISTRY
AND BIOCHEMISTRY OF THE CAS
Ústav organické chemie a biochemie AV ČR,
v.v.i.**

By: [REDACTED]

Name: Steven L. Kousouris

Title: Executive Director

Johns Hopkins Technology Ventures

Date: 12/5/2023

By: [REDACTED]

Name: Prof. RNDr. Jan Konvalinka, CSc.


Title: Director

Date: December 11, 2023

[REDACTED]

[Redacted]

Exhibit A:



[Redacted]